The SUMMIT trial, involving 731 individuals with HFpEF and obesity followed for a median of 104 weeks, revealed a 38% decrease in the composite endpoint of cardiovascular mortality or heart-failure deterioration events (HR: 0.62, 95%CI: 0.41-0.95, P = 0.026), driven primarily by fewer worsening heart-failure events (8.0% vs
Being led to believe an herbal patch is equivalent to a prescription medication is misinformation
Research Use Only These products are for laboratory research only and not intended for medical use
Researchers dont know exactly why theres a gap between womens and responses to GLP-1s, but a few theories are emerging: The same GLP-1 dose may be more potent for women
List prices after approval may land in the $900 to $1,300 range prior to rebates or discounts
Thats why we created our GLP-1 Support High Potency Multi